Crinetics Pharmaceuticals (NASDAQ:CRNX) & Towa Pharmaceutical (OTCMKTS:TWAPF) Head to Head Analysis

Towa Pharmaceutical (OTCMKTS:TWAPF) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Profitability

This table compares Towa Pharmaceutical and Crinetics Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Towa Pharmaceutical	N/A	N/A	N/A
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Insider & Institutional Ownership

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Towa Pharmaceutical and Crinetics Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Towa Pharmaceutical	N/A	N/A	N/A	N/A	N/A
Crinetics Pharmaceuticals	$7.70 million	1,166.77	-$465.32 million	($5.04)	-16.81

Towa Pharmaceutical has higher earnings, but lower revenue than Crinetics Pharmaceuticals.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Towa Pharmaceutical and Crinetics Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Towa Pharmaceutical	0	0	1	0	3.00
Crinetics Pharmaceuticals	1	11	5	0	2.24

Crinetics Pharmaceuticals has a consensus price target of $81.00, suggesting a potential downside of 4.37%. Given Crinetics Pharmaceuticals’ higher possible upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Towa Pharmaceutical.

Summary

Crinetics Pharmaceuticals beats Towa Pharmaceutical on 5 of the 9 factors compared between the two stocks.

About Towa Pharmaceutical

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It also offers IT service related to healthcare; and disease risk testing services. In addition, the company is involved with research and development of diagnostic drugs; and planning, development and OEM manufacturing of health food, pharmaceuticals, general food and other products. The company was founded in 1951 and is headquartered in Osaka, Japan.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.